Brief: BioNTech Starts Phase 3 Trial of Pumitamig Plus Gilead's Trodelvy for Breast Cancer

BioNTech SE

Yesterday 11:49

       Oct 22 (Reuters) - BIONTECH SE  22UAy.DE :
    * ADVANCES PHASE 3 CLINICAL TRIAL OF PUMITAMIG IN
COMBINATION WITH GILEAD’S TROP2-DIRECTED ADC SACITUZUMAB
GOVITECAN IN TRIPLE-NEGATIVE BREAST CANCER
    * CO AND GILEAD TO EVALUATE PUMITAMIG WITH SACITUZUMAB
GOVITECAN IN FIRST-LINE TNBC
    * ROSETTA BREAST-01 PHASE 3 TRIAL EVALUATES PUMITAMIG IN
TRIPLE-NEGATIVE BREAST CANCER
    * UNDER TERMS OF AGREEMENT, BIONTECH WILL CONTINUE TO
SPONSOR AND LEAD ROSETTA BREAST-01 TRIAL
    * GILEAD WILL SUPPLY SACITUZUMAB GOVITECAN FOR COMBINATION
TRIAL

    Source text:  ID:nGNX5xXbyM 
    Further company coverage:  22UAy.DE 
    

    (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))